Fig. 2: Cumulative incidence of study outcomes in patients with chronic kidney disease and type 2 diabetes.

A MACE. B MAKE. C All-cause mortality. Kaplan–Meier curves show estimated survival/event-free probabilities for each treatment group (centre), with shaded areas indicating 95% confidence intervals (error bands). The number at risk and the number of events at each time point are shown below each panel. Sample sizes for both finerenone and spironolactone groups are n = 1132, with each patient representing an independent biological replicate. P values were calculated using a two-sided log-rank test. Exact p values are provided where available; otherwise, p values are reported as <0.001 when below this threshold. No adjustments were made for multiple comparisons. Source data are provided as a Source data file. MACE major adverse cardiac events, MAKE major adverse kidney events.